Details

Autor(en) / Beteiligte

• Dadwal, Sanjeet S.
• Papanicolaou, Genovefa A.
• Boeckh, Michael

Titel

How I prevent viral reactivation in high-risk patients

Ist Teil von

• Blood, 2023-04, Vol.141 (17), p.2062-2074

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• [Display omitted] Preventing viral infections at an early stage is a key strategy for successfully improving transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been successfully used to prevent clinically significant viral infections in hematopoietic cell transplant recipients. Major progress has been made over the past decades in preventing viral infections through a better understanding of the biology and risk factors, as well as the introduction of novel antiviral agents and advances in immunotherapy. High-quality evidence exists for the effective prevention of herpes simplex virus, varicella-zoster virus, and cytomegalovirus infection and disease. Few data are available on the effective prevention of human herpesvirus 6, Epstein-Barr virus, adenovirus, and BK virus infections. To highlight the spectrum of clinical practice, here we review high-risk situations that we handle with a high degree of uniformity and cases that feature differences in approaches, reflecting distinct hematopoietic cell transplant practices, such as ex vivo T-cell depletion. Viral infection remains a serious cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Using a series of 5 illustrative cases, Dadwal and colleagues discuss preventative and preemptive therapy for the management of viral infections in patients undergoing HSCT.